NCT06376474

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Liver Damage

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild, Moderate Liver Impairment and Normal Liver Function After a Single Oral Administration

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study was to evaluate the pharmacokinetics of Hemay 005 tablets in subjects with mild, moderate liver impairment and normal liver function, and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment.

Detailed description

To evaluate the pharmacokinetics and safety of Hemay 005 tablets in subjects with mild, moderate liver impairment and normal liver function, and to provide a basis for the formulation of clinical medication regimens for patients with liver impairment.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Hemay005	15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Timeline

• Start date: 2024-04-28
• Primary completion: 2025-12-10
• Completion: 2025-12-31
• First posted: 2024-04-19
• Last updated: 2025-12-04

Locations

1 site across 1 country: China